Registro:

Referencias:

• D'Alonzo, G.G., Barst, R.J., Ayres, S.M., Survival in patients with primary pulmonary hypertension: Results from a natural prospective registry (1991) Ann Intern Med, 115, pp. 343-349
• Humbert, M., Sitbon, O., Chaouat, A., Pulmonary arterial hypertension in France: Results from a national registry (2006) Am J Respir Crit Care Med, 173, pp. 1023-1030
• Peacock, A.J., Murphy, N.F., McMurray, J.J., An epidemiological study of pulmonary arterial hypertension (2007) Eur Respir J, 30, pp. 104-109
• Thenappan, T., Shah, S.J., Rich, S., A USA-based registry for pulmonary arterial hypertension: 1982-2006 (2007) Eur Respir J, 30, pp. 1103-1110
• Lauga, A., D'Ortencio, A., Monitoreo de las presiones de la arteria pulmonar: Catéter de Swan-Ganz. Parte I (2007) Insuf Card, 2 (1), pp. 5-11
• Gaine, S.P., Rubin, L.J., Primary pulmonary hypertension (1998) Lancet, 352, pp. 719-725
• Bortman, G., Presentación clínica y clasificación actual de la hipertensión arterial pulmonar (2009) Insuf Card, 4 (1), pp. 27-32
• Melero, M.J., Estado actual de la hipertensión arterial pulmonar (2009) Insuf Card, 4 (1), pp. 23-26
• Thierer, J., Importancia del diagnóstico precoz en la hipertensión pulmonar (2009) Insuf Card, 4 (2), pp. 52-58
• Barst, R.J., McGoon, M., Torbicki, A., Diagnosis and differential assessment of pulmonary hypertension (2004) J Am Coll Cardiol, 43, pp. 40S-47S
• Baim, D.S., (2005) Grossman's Cardiac Catheterization, Angiography, and Intervention, , ed., 7th ed. Philadelphia, Penn: Lippincott/ Williams &Wilkins
• Rich, S., McLaughhlin, V., Pulmonary Hypertension (2005) Braunwalds Heart Disease, pp. 1807-1842. , En:, Zioes D, Libby P, Bonow R, Braunwald E, eds. Elsevier Saunders, 7ed
• McLaughlin, V.V., McGoon, M.D., Pulmonary arterial hypertension (2006) Circulation, 114, pp. 1417-1431
• Ruiz Cano, M.J., Tello, M.R., Delgado, J.F., Aproximación diagnóstica al paciente con hipertensión arterial pulmonar (2009) Tratado de hipertensión arterial pulmonar, pp. 71-96. , En:, Sueiro B, Gaudo JI, eds. Ars Médica Barcelona
• Masuyama, T., Kodama, K., Kitakabe, A., Continuous-wave Doppler echocardiographic detection of pulmonary regurgitation and its application to noninvasive estimation of pulmonary artery pressure (1986) Circulation, 74, pp. 484-492
• Bichara, V.M., Tazar, J., Ventura, H.O., El ecocardiograma como herramienta para el diagnóstico y la evaluación de los pacientes con insuficiencia cardíaca (2010) Insuf Card, 5 (2), pp. 51-58
• Tazar, J., Haurigot, M.P., Caram, R., Haurigot, G.E., Función sistólica del ventrículo derecho en pacientes con hipertensión pulmonar: Análisis con strain y strain rate (2012) Insuf Card, 7 (3), pp. 109-116
• Berger, M., Haimowitz, A., van Tosh, A., Berdoff, R.L., Golberg, E., Quantitative assessment of pulmonary hypertension in patient with tricuspid regurgitation using continuous wave Doppler ultrasound (1985) J Am Coll Cardiol, 6 (2), pp. 359-365
• Simonneau, G., Robbins, I., Beghetti, M., Updated Clinical Classification of Pulmonary Hypertension (2009) J Am Coll Cardiol, 54, pp. S43-S54
• Hoeper, M.M., Barbera, J.A., Channick, R.N., Diagnosis, Assessment, and treatment of nonpulmonary arterial hypertension pulmonary hypertension (2009) J Am Coll Cardiol, 54, pp. S85-S96
• Naval, N., Clasificación actual de la hipertensión pulmonar (2011) Insuf Card, 6 (1), pp. 30-38
• Naval, N., Epidemiología de la hipertensión pulmonar (2010) Insuf Card, 5 (4), pp. 192-196
• Rubin, L.J., Primary pulmonary hypertension (1997) N Engl J Med, 336, pp. 111-117
• Fuster, V., Steele, P.M., Edwards, W.D., Primary pulmonary hypertension: Natural history and the importance of thrombosis (1984) Circulation, 70, pp. 580-587
• Simonneau, G., Galie, N., Rubin, L., Clinical classification of pulmonary hypertension (2004) J Am Coll Cardiol, 43 (SUPPL.), pp. S5-S12
• Rich, S., Dantzker, D.R., Ayres, S.M., Primary pulmonary hypertension. A national prospective study (1987) Ann Intern Med, 107, pp. 216-223
• Rich, S., (1998) Primary Pulmonary Hypertension: Executive Summary From the World Symposium on Primary Pulmonary Hypertension, , Evian, France: World Health Organization
• Barimboim, E., Hipertensión pulmonar en las enfermedades del tejido conectivo: Nuevas perspectivas ante un problema de difícil resolución (2009) Insuf Card, 4 (3), pp. 101-106
• Sánchez Román, J., Diagnóstico y tratamiento de la hipertensión pulmonar en pacientes con esclerodermia (2012) Insuf Card, 7 (1), pp. 16-28
• Peacock, A.J., Treatment of pulmonary hypertension (2003) BMJ, 326, pp. 835-836
• McGoon, M., Gutterman, D., Steen, V., Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines (2004) Chest, 126, pp. 14S-34S
• Badesch, D.B., Abman, S.H., Simonneau, G., Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines (2007) Chest, 131, pp. 1917-1928
• Bichara, V.M., Ventura, H.O., Perrone, S.V., Hipertensión pulmonar: La mirada del especialista (2011) Insuf Card, 6, pp. 65-79
• Mazzei, J.A., Cáneva, J.O., Perrone, S.V., Melero, M.J., Scali, J.J., Bortman, G., Actualización en el diagnóstico y tratamiento de la hipertensión pulmonar (2011) Medicina (B. Aires), 71 (SUPPL. 1), pp. 1-48
• Caroli, C., Yaman, B., Embón, M., Cohen Arazi, H., Perrone, S.V., Resonancia magnética nuclear en la evaluación de la hipertensión pulmonar (2009) Insuf Card, 4 (2), pp. 82-84
• Perrone, S.V., Estrategia terapéutica en el tratamiento de la hipertensión arterial pulmonar (2009) Insuf Card, 4 (1), pp. 33-43
• McLaughlin, V.V., Archer, S.L., Badesch, D.B., ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents (2009) J Am Coll Cardiol, 53, pp. 1573-1619
• Farber, H.W., Loscalzo, J., Pulmonary arterial hypertension (2004) N Engl J Med, 351, pp. 1655-1665
• Badesch, D.B., Champion, H.C., Gomez Sanchez, M.A., Diagnosis and assessment of pulmonary arterial hypertension (2009) J Am Coll Cardiol, 54, pp. S55-S66
• Mazzei, J.A., Mecanismos fisiopatológicos involucrados y diagnóstico de la hipertensión arterial pulmonar (2009) Insuf Card, 4 (1), pp. 3-10
• Wigley, F.M., Lima, J.A., Mayes, M., The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study) (2005) Arthritis Rheum, 52, pp. 2125-2132
• Koh, E.T., Lee, P., Gladman, D.D., Pulmonary hypertension in systemic sclerosis: An analysis of 17 patients (1996) Br J Rheumatol, 35, pp. 989-993
• Vongpatanasin, W., Brickner, M., Hillis, L.D., The Eisenmenger Syndrome in adults (1998) Ann Intern Med, 128, pp. 745-755
• Cappola, T.P., Felker, G.M., Kao, W.H., Pulmonary hypertension and risk of death in cardiomyopathy (2002) Circulation, 105, pp. 1663-1668
• Krowka, M.J., Hepatopulmonary syndromes (2000) Gut, 46, pp. 1-4
• Newman, J.H., Fanburg, B.L., Archer, S.L., Pulmonary arterial hypertension: Future directions: Reports of a National Heart, Lung and Blood Institute/Office of Rare Disease Workshop (2004) Circulation, 109, pp. 2947-2952
• Lepetit, H., Eddahibi, S., Fadel, E., Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension (2005) Eur Respir J, 25, pp. 834-842
• Begnini, A., Remuzzi, G., Endothelin antagonists (1999) Lancet, 353, pp. 133-138
• Giaid, A., Yanagisawa, M., Langleben, D., Expression of endothelin-1in the lungs of patients of pulmonary hypertension (1993) N Engl J Med, 328, pp. 1732-1739
• Stewart, D.J., Levy, R.D., Cernacek, P., Increase plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? (1991) Ann Intern Med, 114, pp. 464-469
• Tuder, R.M., Cool, C.D., Geraci, M.W., Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension (1999) Am J Respir Crit Care Med, 159, pp. 1925-1932
• Cristman, B.W., McPherson, C.D., Newman, J.H., An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension (1992) N Engl J Med, 237, pp. 70-75
• Giaid, A., Saleh, D., Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension (1993) N Engl J Med, 333, pp. 214-221
• Cella, G., Bellotto, F., Toma, F., Plasma markers of endothelial dysfunction in pulmonary hypertension (2001) Chest, 120, pp. 1226-1230
• Lincoln, T.M., Cyclic GMP and phosphodiesterase 5 inhibitor therapies: What's on the horizon? (2004) Mol Pharmacol, 66, pp. 11-13
• Eddahibbi, S., Humbert, M., Fadel, E., Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension (2001) J Clin Invest, 108, pp. 1141-1150
• Guignabert, C., Izikki, M., Ieng, L., Transgenic mice overexpressing the 5-Hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension (2006) Circ Res, 98, pp. 1323-1330
• Petkov, V., Mosgeoller, W., Ziesche, R., Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension (2003) J Clin Invest, 111, pp. 1339-1346
• Eddahibbi, S., Morrell, N., D'Ortho, M.-P., Pathobiology of pulmonary arterial hypertension (2002) Eur Respir J, 20, pp. 1559-1572
• Rich, S., Primary pulmonary hypertension (1988) Prog Cardiovasc Dis., 31, pp. 205-238
• Davie, N., Haleen, S.J., Upton, P.D., ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells (2002) Am J Respir Crit Care Med, 165, pp. 398-405
• Nishida, M., Eshiro, K., Okada, Y., Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension in rats (2004) J Cardiovasc Pharmacol, 44, pp. 187-191
• Sauvageau, S., Thorin, E., Caron, A., Endothelin-1-induced pulmonary vasoreactivity is regulated by ETA and ETB receptor interactions (2007) J Vasc Res, 44, pp. 375-381
• Sauvageau, S., Thorin, E., Caron, A., Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction (2006) Exp Biol Med (Maywood), 231, pp. 840-846
• McLean, M.R., Docherty, C.C., McCulloch, K.M., Effect of novel mixed ETA/ETB antagonists on responses to ET-1 in human small muscular pulmonary arteries (1998) Pulm Pharmacol Ther, 11, pp. 147-149
• Jasmin, J.F., Lucas, M., Cernacek, P., Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension (2001) Circulation, 103, pp. 314-318
• Dupuis, J., Hoeper, M.M., Endothelin receptor antagonists in pulmonary arterial hypertension (2008) Eur Respir J, 31, pp. 407-415
• Rosenblum, W.D., Pulmonary Arterial Hypertension. Pathobiology, Diagnosis, Treatment, and Emerging Therapies (2010) Cardiology in Review, 18, pp. 58-63
• Williamson, D.J., Wallman, L.L., Jones, R., Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension (2000) Circulation, 102, pp. 411-418
• Channick, R.N., Simonneau, G., Sitbon, O., Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomized placebo-controlled study (2001) Lancet, 358, pp. 1119-1123
• Grignola, J.C., Gómez Sánchez, M.A., Bosentan: Rol en el tratamiento de la hipertensión arterial pulmonar (2009) Insuf Card, 4 (1), pp. 11-22
• Kaplinsky, E.J., Utilidad del bosentan en la hipertensión pulmonar tromboembólica crónica: Estudio BENEFIT (2008) Insuf Card, 3 (2), pp. 63-64
• Rubin, L.J., Badesch, D.B., Barst, R.J., Bosentan therapy for pulmonary arterial hypertension (2002) N Engl J Med, 346, pp. 846-903
• Galiè, N., Rubin, L.J., Hoeper, M.M., Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): A double-blind, randomised controlled trial (2008) Lancet, 371, pp. 2093-2100
• McLaughlin, V.V., Sitbon, O., Badesch, D.B., Survival with first-line bosentan in patients with primary pulmonary hypertension (2005) Eur Respir J, 25, pp. 244-249
• Provencher, S., Sitbon, O., Humbert, M., Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension (2006) Eur Heart J, 27, pp. 589-595
• Keogh, A.M., McNeil, K.D., Wlodarczyk, J., Quality of life in pulmonary arterial hypertension: Improvement and maintenance with bosentan (2007) J Heart Lung Transplant, 26, pp. 181-187
• Barst, R.J., Ivy, D., Dingemanse, J., Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension (2003) Clin Pharmacol Ther, 73, pp. 372-382
• Rosenzweig, E.B., Ivy, D.D., Widlitz, A., Effects of longterm bosentan in children with pulmonary arterial hypertension (2005) J Am Coll Cardiol, 46, pp. 697-704
• Sitbon, O., Gressin, V., Speich, R., Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension (2004) Am J Respir Crit Care Med, 170, pp. 1212-1217
• Degano, B., Yaïci, A., le Pavec, J., Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension (2009) Eur Respir J, 33, pp. 92-98
• Galiè, N., Beghetti, M., Gatzoulis, M.A., Bosentan therapy in patients with Eisenmenger syndrome. A multicenter, double-blind, randomized, placebo-controlled study (2006) Circulation, 114, pp. 48-54
• Denton, C.P., Humbert, M., Rubin, L., Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: A subgroup analysis of the pivotal clinical trials and their open-label extensions (2006) Ann Rheum Dis, 65, pp. 1336-1340
• Wilkins, M.R., Paul, G.A., Strange, J.W., Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study (2005) Am J Respir Crit Care Med, 171, pp. 1292-1297
• Galiè, N., Badesch, D., Oudiz, R., Ambrisentan therapy for pulmonary arterial hypertension (2005) J Am Coll Cardiol, 46, pp. 529-535
• Galiè, N., Olschewski, H., Oudiz, R.J., Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2 (2008) Circulation, 117, pp. 3010-3019
• Oudiz, R.J., Galiè, N., Olschewski, H., Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension (2009) J Am Coll Cardiol, 54, pp. 1971-1981
• Badesch, D.B., Feldman, J., Keogh, A., ARIES-3: Ambrisentan therapy in a diverse population of patients with pulmonary hypertension [abstract] (2009) Am J Respir Crit Care Med, 179, pp. A3357
• (2009) Tracleer prescribing information, , South San Francisco, CA: Actelion Pharmaceuticals
• Humbert, M., Segal, E.S., Kiely, D.G., Results of European post-marketing surveillance of bosentan in pulmonary hypertension (2007) Eur Respir J, 30, pp. 338-344
• McGoon, M.D., Frost, A.E., Oudiz, R.J., Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities (2009) Chest, 135, pp. 122-129
• Paul, G.A., Gibbs, J.S., Boobis, A.R., Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension (2005) Br J Clin Pharmacol, 60, pp. 107-112
• Ghofrani, H.A., Rose, F., Schermuly, R.T., Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension (2003) J Am Coll Cardiol, 42, pp. 158-164
• Hoeper, M.M., Faulenbach, C., Golpon, H., Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension (2004) Eur Respir J, 24, pp. 1007-1010
• Hoeper, M.M., Taha, N., Bekjarova, A., Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids (2003) Eur Resp J, 22, pp. 330-334
• Humbert, M., Barst, R.J., Robbins, I.M., Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 (2004) Eur Respir J, 24, pp. 353-359
• McLaughlin, V.V., Oudiz, R.J., Frost, A., Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension (2006) Am J Respir Crit Care Med, 174, pp. 1257-1263
• Hoeper, M.M., Leuchte, H., Wilkens, H., Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension (2006) Eur Resp J, 28, pp. 691-694
• Mathai, S.C., Girgis, R.E., Fisher, M.R., Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension (2007) Eur Respir J, 29, pp. 469-475
• Savale, L., Sitbon, O., le Pavec, J., Addition of sildenafil to first line bosentan therapy in patients with idiopathic pulmonary arterial hypertension [abstract] (2009) Am J Respir Crit Care Med, 179 (SUPPL.), pp. A3368
• Simonneau, G., Rubin, L.J., Galiè, N., Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension (2008) Ann Intern Med, 149, pp. 521-530
• Bendayan, D., Shitrit, D., Kramer, M.R., Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: A pilot study (2008) Respirology, 13, pp. 916-918
• Hoeper, M.M., Faulenbach, C., Golpon, H., Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension (2004) Eur Respir J, 24, pp. 1007-1010. , Abstract
• Mathai, S.C., Girgis, R.E., Fisher, M.R., Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension (2007) Eur Respir J, 29, pp. 469-475
• Gruenig, Michelakis, Vachiery, COMPASS-1 (2007) Eur Heart J, 28 (SUPPL.), p. 140
• Torres, F., Gupta, H., Murali, S., Goal-directed combination therapy in pulmonary arterial hypertension (PAH): Study design of COMPASS-3 (2007) Chest, 132, pp. 633S
• Benza, R.L., Gupta, H., Soto, F.J., Park, M.H., Torres, F., Frey, N., Murali, S., Safety and Efficacy of Bosentan in Combination With Sildenafil in PAH Patients Who Experience Inadequate Clinical Response to Monotherapy: The COMPASS-3 Study (2010) Chest, 138 (4), pp. 840A. , MeetingAbstracts
• Kawut, S.M., Palevsky, H.I., Surrogate end points for pulmonary arterial hypertension (2004) Am Heart J, 148, pp. 559-565. , Abstract
• Effects of the combination of bosentan and sildenafil versus sildenafil monotherapy on pulmonary arterial hypertension (PAH) (COMPASS 2), , http://www.clinicaltrials.gov/ct2/show/NCT00303459, Available at:
• Humbert, M., Barst, R.J., Robbins, I.M., Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 (2004) Eur Respir J, 24, pp. 353-359. , Abstract
• McLaughlin, V.V., Oudiz, R.J., Frost, A., Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension (2006) Am J Respir Crit Care Med, 174, pp. 1257-1263. , Abstract
• Frost, A.E., Step-open label extension: Long-term benefits of inhaled iloprost (ILO) addition to bosentan for treatment of pulmonary arterial hypertension (PAH) (2007) Am J Resp Crit Care Med, 175, pp. A1001. , the Step Investigators
• McLaughlin, V., Rubin, L., Benza, R., TRIUMPH 1: Efficacy and safety of inhaled treprostinil sodium in patients with pulmonary arterial hypertension (2008) Am Rev Resp Crit Care Med, 177, pp. A965
• Hoeper, M.M., Markevych, I., Spiekerkoetter, E., Goaloriented treatment and combination therapy for pulmonary arterial hypertension (2005) Eur Respir J, 26, pp. 858-863
• Galie, N., Manes, A., Negro, L., A meta-analysis of randomized controlled trials in pulmonary arterial hypertension (2009) Eur Heart J, 30, pp. 394-403
• Sitbon, O., Morrell, N.W., Pathways in pulmonary arterial hypertension: The future is here (2012) Eur Respir Rev, 21 (126), pp. 321-327
• Humbert, M., Souza, R., Galiè, N., McLaughlin, V., Simonneau, G., Rubin, L., Pulmonary arterial hypertension: Bridging the present to the future (2012) Eur Respir Rev, 21 (126), pp. 267-270

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------